# KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

> **NCT05603572** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Primocure Pharma** · enrollment: 148 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Fibrolamellar Carcinoma

## Interventions

- **DRUG:** KAT-101
- **DRUG:** KAT-201

## Key facts

- **NCT ID:** NCT05603572
- **Lead sponsor:** Primocure Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-11-01
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 148 (ESTIMATED)
- **Why stopped:** Enrollment paused
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603572, "KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05603572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*